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Abstract
Background: An inverse correlation between expression of the aldehyde dehydrogenase 1 subfamily A2 (ALDH1A2)
and gene promoter methylation has been identified as a common feature of oropharyngeal squamous cell carcinoma
(OPSCC). Moreover, low ALDH1A2 expression was associated with an unfavorable prognosis of OPSCC patients,
however the causal link between reduced ALDH1A2 function and treatment failure has not been addressed so far.
Methods: Serial sections from tissue microarrays of patients with primary OPSCC (n = 101) were stained by
immunohistochemistry for key regulators of retinoic acid (RA) signaling, including ALDH1A2. Survival with respect to
these regulators was investigated by univariate Kaplan-Meier analysis and multivariate Cox regression proportional
hazard models. The impact of ALDH1A2-RAR signaling on tumor-relevant processes was addressed in established
tumor cell lines and in an orthotopic mouse xenograft model.
Results: Immunohistochemical analysis showed an improved prognosis of ALDH1A2high OPSCC only in the presence
of CRABP2, an intracellular RA transporter. Moreover, an ALDH1A2highCRABP2high staining pattern served as an
independent predictor for progression-free (HR: 0.395, p = 0.007) and overall survival (HR: 0.303, p = 0.002), suggesting a
critical impact of RA metabolism and signaling on clinical outcome. Functionally, ALDH1A2 expression and activity in
tumor cell lines were related to RA levels. While administration of retinoids inhibited clonogenic growth and
proliferation, the pharmacological inhibition of ALDH1A2-RAR signaling resulted in loss of cell-cell adhesion and a
mesenchymal-like phenotype. Xenograft tumors derived from FaDu cells with stable silencing of ALDH1A2 and primary
tumors from OPSCC patients with low ALDH1A2 expression exhibited a mesenchymal-like phenotype characterized by
vimentin expression.
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Conclusions: This study has unraveled a critical role of ALDH1A2-RAR signaling in the pathogenesis of head and neck
cancer and our data implicate that patients with ALDH1A2low tumors might benefit from adjuvant treatment with
retinoids.
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Background
Squamous cell carcinoma of the head and neck (HNSCC)
represents one of the most prevalent and lethal human
malignancies worldwide, with only a few therapeutic op-
tions of limited clinical benefit, available [1]. Conse-
quently, appropriate treatment of advanced HNSCC still
remains a major challenge for translational oncology, and
there is an urgent need for reliable prognostic biomarkers
for treatment failure, as well as innovative drug targets for
more effective and less toxic therapy [2]. Functional gen-
omic approaches including global gene expression profiling
and whole-exome sequencing have yielded new insights
into the molecular principles underlying the pathogenesis
and have highlighted the presence of therapeutic candidates
in most primary HNSCC [3–5]. However, the causal link
and clinical relevance of most differentially expressed genes
and somatic mutations for tumor progression and patient
survival remains to be addressed considering the extremely
high inter- and intratumoral heterogeneity of HNSCC.
In addition to genetic events, aberrant DNA hyper-
methylation has been linked with the etiology, pathogenesis
and clinical outcome of HNSCC patients [6, 7]. How-
ever, our knowledge on how distinct genetic and epigenetic
alterations affect the tumor response to established or
novel therapeutic interventions is still limited.
Previously, we have conducted global DNA methylome
analysis on samples of oropharyngeal SCCs (OPSCC),
which showed a specific signature of gene promoter
methylation that predicted improved clinical outcome in
three independent patient cohorts [8]. One candidate
gene from our prognosticator encodes for the aldehyde
dehydrogenase 1 subfamily member A2 (ALDH1A2),
and low ALDH1A2 protein levels served as unfavorable
prognostic biomarker for the survival of OPSCC patients
[8]. ALDH1A2 is the rate-limiting enzyme in the cellular
synthesis of the vitamin A metabolite retinoic acid (RA),
which regulates multiple biological processes during em-
bryonic development and in adult tissue remodeling and
homeostasis [9]. RA mainly exerts its biological function,
including cell differentiation, cell cycle arrest, and even-
tually apoptosis, through binding to nuclear RA recep-
tors (RAR) [10–12]. Upon ligand binding, RARs form
heterodimers with retinoid X receptors (RXR) and func-
tion as ligand-dependent transcription factors to activate
downstream target genes containing RA response ele-
ments (RARE) [11]. In addition to this classical pathway,
RARs and RXRs can form heterodimers with other types
of nuclear receptors, including the estrogen receptor
(ER), peroxisome proliferator-activated receptor (PPAR),
liver X receptors (LXR), and vitamin D receptor (VDR)
[12]. Interestingly, these non-classical pathways often
regulate cellular processes that have functions opposite
to the classical pathway.
RA and related synthetic products display potent anti-
cancer activity in certain human malignancies, such as
promyelocytic leukemia, which is mainly mediated by
activation of the classical RA pathway and forms the
basis for its therapeutic application [13, 14]. Although
pharmacologic doses of RA derivatives have been effect-
ive in the treatment of hematologic malignancies, clin-
ical trials in the prevention and treatment setting of
solid tumors, including HNSCC, have failed to show sig-
nificant benefit [15]. Notably some carcinomas not only
fail to become growth inhibited upon treatment with
RA, but respond with enhanced proliferation upon treat-
ment. A clue to this paradoxical behavior was recently
suggested by the findings that RA also activates PPARβ/
δ, a receptor involved in mitogenic and anti-apoptotic
activities [16]. In this context, it is worth noting that the
distribution of RA between distinct nuclear receptors is
regulated by two intracellular lipid-binding proteins,
namely cellular RA binding protein 2 (CRABP2), which
targets RA to RAR, and fatty acid binding protein 5
(FABP5), which delivers it to PPARβ/δ.
In the current study, we addressed the questions whether
improved clinical outcome of ALDH1A2-positive tumors
depends on the presence of key regulators of RA signaling.
Moreover, we demonstrate that inhibition of ALDH1A2-
RAR signaling induces a mesenchymal-like phenotype in
vitro as well as in vivo, suggesting that patients with
ALDH1A2low tumors might benefit from treatment with
retinoids or restoration of ALDH1A2 function.
Results
Clinical outcome of ALDH1A2high tumors depends on the
presence of CRABP2
To address the question, whether improved clinical out-
come of ALDH1A2high tumors is related to the presence
of key components of RA signaling, immunohistochemi-
cal staining was conducted on serial sections of tissue
microarrays consisting of samples from primary OPSCC
for which ALDH1A2 protein levels were determined
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previously [8]. Prominent nuclear staining of the in-
tracellular transporters CRABP2 and FABP5, as well as
nuclear receptors RARα, RARβ and PPARβ/δ were
detected in basal and supra-basal keratinocytes of nor-
mal mucosa, while a more heterogeneous expression
pattern concerning staining intensity and intracellular
localization of all five proteins was found in tumor cells
(Fig. 1a). The expression patterns of the individual pro-
teins were evaluated according to the relative amount of
positive tumor cells and the corresponding staining in-
tensity, and investigated with respect to their prognostic
value on overall survival (OS). Univariate Kaplan-Meier
analysis revealed a significant better OS for CRABP2high as
compared to CRABP2low as well as for FABP5high as com-
pared to FABP5low protein levels, respectively (Additional
file 1: Figure S1A-B). In contrast, no significant correlation
was found for RARα, RARβ or PPARβ/δ protein levels
and OS (Additional file 1: Figure S1C-E). Whilst protein
levels of CRABP2 and FABP5 correlated with OS, their
expression was not associated with any clinical or
pathological feature tested (Additional file 2: Table S3-4).
Integrative subgroup analysis showed that ALDH1A2high
tumors with CRABP2high expression had a significantly
higher probability for improved OS, which was inde-
pendent of the FABP5 staining pattern (Additional file 1:
Figure S1F). In contrast, ALDH1A2high tumors in the
absence of CRABP2 had a poor prognosis similar to
ALDH1A2low tumors (Fig. 1b). Multivariate Cox regres-
sion models confirmed that the combined staining pattern
of ALDH1A2highCRABP2high served as an independent
predictor for PFS and OS of OPSCC patients, when ad-
justed for gender, age, clinical stage, tobacco and alcohol
consumption, type of first-line therapy and HPV status
(Table 1). In summary these data strongly supported the as-
sumption that improved clinical outcome of ALDH1A2high
OPSCCs critically depends on CRABP2-related RA metab-
olism and signaling.
ATRA treatment impairs clonogenic growth of ALDH1A2-
negative Cal27 cells
The data presented so far proposed a model in which
patients with ALDH1A2low tumors, who are at high risk
for treatment failure might benefit from restoration of
RA availability as long as their tumor cells express
CRABP2. To further support this model, several human
HNSCC cell lines were screened by Western blot ana-
lysis and prominent ALDH1A2 expression was found in
FaDu, UMSCC, Detroit 562, SCC25, Lau2068, Lau2104
and Lau2105, but not Cal27, Lau2073 and Lau2081 cell
lines (Fig. 2a and Additional file 3: Figure S2A-B). FaDu
and Cal27 cells were selected for further analysis as both
cell lines expressed similar amounts of CRABP2 and
other components of RA signaling, but differed in
ALDH1A2 expression. HPLC analysis revealed a two-
fold higher concentration of intracellular RA levels in
FaDu as compared to Cal27 cells and treatment with the
ALDH1A2 inhibitor WIN18.446 reduced relative RA
levels almost two-fold in FaDu but not Cal27 cells
(Additional file 3: Figure S2C-D), supporting a positive
association between the presence of ALDH1A2 and RA
metabolism.
Next, the sensitivity of FaDu and Cal27 cells to activa-
tion of RA signaling was determined by a colony-
forming assay (CFA). Both cell lines were treated every
second day with all-trans retinoic acid (ATRA) and their
clonogenic growth was monitored after two weeks
(Fig. 2b-c). A concentration dependent decrease in the
survival fraction for both cell lines was observed. How-
ever, ALDH1A2-negative Cal27 cells exhibited a more
pronounced response (effective dose ED50 ≈ 1 μM) as
compared to FaDu cells (ED ≈ 44 μM). A similar trend
was also observed after treatment with Adapalene or
Fenretinide, respectively, which belong to the new gener-
ation of synthetic retinoids (Additional file 3: Figure
S2E-F). Similar to FaDu cells, ALDH1A2-positive De-
troit562 and UMSCC-17B cells exhibited a higher resist-
ance to ATRA administration in a colony-forming assay
(Additional file 4: Figure S3B). Impaired clonogenic
growth of Cal27 cells after ATRA treatment was consist-
ent with reduced proliferation as determined by BrdU
incorporation (Fig. 2d), which was not found for
ALDH1A2-positive cell lines tested (Additional file 4:
Figure S3A). Furthermore, treatment with 3 μM ATRA
sensitized Cal27 cells to irradiation at a dose of 2 Gy, but
had no or only a minor effect on ALDH1A2-postitive cells
(Fig. 2e and Additional file 4: Figure S3B). The radiosensi-
tization of Cal27 cells by ATRA was associated by a con-
centration dependent increase in cleaved caspase 3 levels,
indicating accelerated apoptosis by the combined treat-
ment (Fig. 2f). These data provided further experimental
evidence that loss ALDH1A2 expression could serve as
surrogate marker for HNSCC patients, who might benefit
from a treatment with retinoids.
Inhibition of ALDH1A2-RAR signaling induces loss of cell
adhesion and gain of a mesenchymal-like phenotype
To address the mode of action, of how reduced
ALDH1A2-RAR signaling impacts tumor-related pro-
cesses, FaDu cells were cultured in the presence of the
ALDH1A2 inhibitor WIN18.446 or BMS493, an inverse
agonist of pan-RAR, which induces nuclear co-repressor
interaction with RARs. Control treated cells exhibited an
epithelial morphology and formed well-defined clusters
with tight cell-cell junctions (Fig. 3a, upper row). In con-
trast, inhibitor-treated cells showed loss of cell-cell junc-
tions and a scattered phenotype within 3 days, and after
6 days in culture with the inhibitors, FaDu cells detached
and developed spheroid-like structures (Fig. 3a, middle
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and lower row). It is worth noting that the severity of
the phenotype was positively correlated with the concen-
tration of both inhibitors (data not shown) and was
more prominent for BMS493. A comparable phenotype
upon WIN18.446 or BMS493 administration was also
observed with Detroit562 cells (Additional file 5: Figure
S4A-B), demonstrating that morphological alterations
after inhibition of ALDH1A2-RAR signaling are not
restricted to FaDu cells. However, UMSCC-17B cells
remained epithelial-like and did not show any sign of
cell scattering, despite prominent ALDH1A2 and RAR
protein expression (Additional file 5: Figure S4A), sug-
gesting a context-dependent response.
In line with the mesenchymal-like morphology both
inhibitors revealed in FaDu cells a significant up-
regulation of vimentin (VIM) and N-cadherin (CDH2)
transcript levels as compared to DMSO-treated controls
(Fig. 3b). Additionally, BMS493-treated cells showed a
transient increase in fibronectin (FN1). However, no sig-
nificant down-regulation in E-cadherin (CDH1) tran-
script levels was detected indicating that inhibition of
ALDH1A2-RAR signaling resulted in only a partial
epithelial-to-mesenchymal transition. We also deter-
mined transcript levels of Snail (SNAI1) and Twist
(TWIST1), two key transcription factors in the induction
and maintenance of EMT, in control and inhibitor
treated FaDu cells. While no major difference was found
for Snail, a significant but transient increase of Twist
was detected with both inhibitors at day 6 (Fig. 3b).
A mesenchymal-like phenotype in epithelial tumor
cells is often associated with higher cell motility. Ac-
cordingly, we conducted a scratch wounding assay with
control, WIN18.446 and BMS493 treated Detroit562 and
FaDu cells. As expected, a clear trend towards acceler-
ated migration was found for both inhibitors as com-
pared to control treated cells, which reached statistical
significance for WIN18.446 at 36 h (Additional file 5:
Figure S4C). Similar data were obtained for FaDu cells
(Additional file 5: Figure S4D).
Silencing of ALDH1A2 expression accelerates tumor
growth in vivo
Finally, the impact of ALDH1A2 loss-of-function on
tumor growth was investigated in vivo by orthotopic in-
jection of stable FaDu-shALDH1A2 or FaDu-mock con-
trol cells in the floor of the mouth of nude mice.
shRNA-mediated silencing of ALDH1A2 protein expres-
sion was confirmed in vitro by Western immunoblot
analysis with whole-cell lysate and in vivo by immuno-
histochemical staining on tumor sections (Fig. 4a-b).
Tumor incidence was comparable for both cell lines (4
out of 5 animals), but FaDu-shALDH1A2 exhibited an
Table 1 Multivariate Cox regression analysis for OS and PFS
Overall survival Progression-free survival
Risk factor HR 95 % CI p-value HR 95 % CI p-value
Gender female vs male 1.016 0.47–2.19 0.967 0.960 0.48–1.94 0.911
Age 0.966 0.49–1.89 0.921 0.862 0.45–1.64 0.650
>57 vs ≤57
Clinical stage 5.699 1.35–24.09 0.018 3.353 1.15–9.77 0.027
III/IV vs I/II
Tobacco current vs. never 0.687 0.15–3.15 0.629 0.431 0.12–1.49 0.184
Tobacco former vs. never 1.261 0.23–6.88 0.789 0.877 0.21–3.60 0.856
Alcohol current vs never 0.786 0.28–2.18 0.644 1.261 0.50–3.16 0.621
Therapy1 radiochemo vs surgery 0.953 0.46–1.98 0.897 0.798 0.40–1.60 0.524
HPV status2 related vs non-related 0.404 0.17–0.96 0.041 0.305 0.13–0.70 0.005
Subgroup 0.303 0.14–0.63 0.002 0.395 0.20–0.77 0.007
ALDH1A2highCRABP2high vs others
HR = Hazard ratio, CI = confidence interval, 1first line treatment, 2related = viral DNA+RNA+, non-related = viral DNA+RNA−or viral DNA−according to [32]
(See figure on previous page.)
Fig. 1 Favorable survival of ALDH1A2high OPSCC depends on the presence of CRABP2. a Representative pictures of IHC stained tissue sections
demonstrate heterogeneous expression (brown signal) of key regulators of RA signaling in keratinocytes of normal mucosa (left panel) and tumor
cells of primary OPSCC (middle and right panel). Counterstaining with hematoxylin to visualize tissue architecture; white bar = 200 μm. b Association
between subgroups with ALDH1A2highCRABP2high (blue line), ALDH1A2highCRABP2low (red line) and ALDH1A2low (green line) staining pattern and
overall survival was assessed by univariate Kaplan-Meier analysis. Number at risk indicates the total amount of patients per subgroup, which were alive
and not censored at the indicated time points and were considered to calculate the overall survival probability. P values were calculated by
log-rank test
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accelerated tumor growth, which was statistical significant
25 days upon injection (Fig. 4c and Additional file 2:
Table S5). While tumor growth was rather homogeneous
in the subgroup of FaDu-shALDH1A2 implanted mice
and all tumors reached the surgical threshold within 29
days, 50 % of FaDu-mock tumors reached a tumor vol-
ume of 250 mm3 between 46–52 days. Accelerated tumor
growth was not related to an obvious increase of Ki67-
positive or a decrease in cleaved caspase 3-positive tumor
cells indicating no major difference in tumor cell prolifera-
tion or apoptosis in vivo (Fig. 4b). However, tumors de-
rived from FaDu-shALDH1A2 cells were characterized by
prominent vimentin expression, which was not detected
for tumors from FaDu-mock controls, and was in line
Fig. 2 ALDH1A2 expression in HNSCC cell lines and impact of ATRA on tumor-related processes. a Western blot analysis with whole cell lysate
demonstrates protein expression of ALDH1A2 and key regulators of RA signaling in FaDu and Cal27 cells. Detection of β-Actin served as control
for quantity and quality of protein lysates. b Representative pictures of a colony-forming assay with Cal27 (upper panel) and FaDu cells (lower
panel), which were cultured in the presence of ATRA at the indicated concentrations or DMSO as control. c The graph represents the relative
survival fraction of Cal27 and FaDu cells following cultivation at the indicated concentration of ATRA. Data represent mean values ± SD of three
independent experiments. d Relative number of BrdU-positive Cal27 cells following treatment with indicated concentrations of ATRA or DMSO as
control. e Relative survival fraction of Cal27 cells after single irradiation with a dose of 2 Gy with or without ATRA treatment (3 μM). Bars represent
mean values + SD of three independent replicates. * p-value ≤ 0.05, *** p-value ≤ 0.0005. f Representative pictures of an immunofluorescence
staining for cleaved caspase 3 (green signal) with Cal27 cells, which were treated with indicated concentrations of ATRA or DMSO as control with
or without irradiation (2 Gy or 5 Gy). Nuclear staining was done with H33324 (blue signal)
Seidensaal et al. Molecular Cancer  (2015) 14:204 Page 6 of 13
Fig. 3 (See legend on next page.)
Seidensaal et al. Molecular Cancer  (2015) 14:204 Page 7 of 13
with the mesenchymal-like phenotype in vitro (Fig. 4b).
Consistent with this result an inverse expression of
ALDH1A2 and vimentin was also evident in primary
OPSCC by immunhistochemical staining of serial tumor
section (Fig. 4d).
Discussion
In the past, gene promoter hyper-methylation and subse-
quent low ALDH1A2 expression was identified as a com-
mon feature for OPSCC and served as a risk factor for an
unfavorable prognosis [8]. Reduced ALDH1A2 levels were
reported previously in tumor cell lines, a mouse tumor
model and tumor specimens of prostate cancer patients
[17, 18]. In these studies low ALDH1A2 expression was
explained, at least in part, by aberrant DNA methylation.
Furthermore, high ALDH1A2 transcript levels correlated
with improved overall survival of breast cancer patients
[19]. Although such data point to a putative tumor sup-
pressor function of ALDH1A2 in the pathogenesis of sev-
eral epithelial cancers, the causal link between loss of
ALDH1A2 function and molecular mechanisms of treat-
ment failure have not been addressed so far.
(See figure on previous page.)
Fig. 3 Pharmacological inhibition of ALDH1A2-RAR signaling induces loss of cell-cell junctions and a mesenchymal-like phenotype. a Representative
brigth field pictures of FaDu cells, which were treated with DMSO, 3 μM WIN18.446 or 3 μM BMS493 for the indicated time points. b FaDu cells were
treated as described in (a) for the indicated time points and relative transcript levels of vimentin (VIM), fibronectin (FN1), N-cadherin (CDH2), E-cadherin
(CDH1), Twist (TWIST1) and Snail (SNAI1) were assessed by quantitative RT-PCR using the ΔΔCT method. Transcript levels of ACTB were
determined as a reference and bars represent mean value + SD of two independent experiments with three replicates. *p-value < 0.05,
**p-value < 0.005, ***p-value < 0.0005
Fig. 4 Impact of stable ALDH1A2 silencing in an orthotopic mouse xenograft model. a Western blot analysis with whole cell lysate of FaDu-mock
and FaDu-shALDH1A2 clones confirms stable silencing of ALDH1A2, while no alteration in RARβ protein level was detected. Detection of β-Actin
served as control for quantity and quality of protein lysates. b Representative pictures of IHC staining with tumor sections derived from FaDu-mock or
FaDu-shALDH1A2-injected xenografts to analyze ALDH1A2 expression, tumor cell proliferation (Ki67), apoptosis (cleaved caspase 3) and the mesenchymal-
like phenotype (Vimentin). Counterstaining with hematoxylin to visualize tissue architecture; scale bar = 20 μm. c The graph represents quantification of
the tumor volume (in mm3) in mice (n = 4 per group) at the indicated time points after implantation with either FaDu-mock or FaDu-shALDH1A2 clones.
Dashed line indicates surgical threshold. Mean values ± SD and p values are given in Additional file 2: Table S5. d Representative pictures of an IHC staining
(brown signal) with serial tumor sections demonstrate inverse expression of ALDH1A2 and vimentin in OPSCC. Counterstaining with hematoxylin to
visualize tissue architecture; white bar = 80 μm
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ALDH1A2 catalysis an irreversible step in the synthesis
of RA and thereby regulates distinct aspects of cell prolif-
eration, differentiation and apoptosis under physiological
and pathological conditions [11, 12]. The anti-tumorigenic
activity of natural and synthetic retinoids on cancer cells
has been established in numerous in vitro and in vivo
models for distinct tumor entities [13, 15]. Accordingly, it
is worth speculating that the detrimental effect of reduced
ALDH1A2 expression on malignant progression and
prognosis is due to impaired RA-dependent signaling.
This assumption is strongly supported by our data dem-
onstrating improved clinical outcome of ALDH1A2high
OPSCC only in the presence of CRABP2, and an over-
lapping phenotype of ALDH1A2-positive FaDu and De-
troit562 cells after pharmaceutical inhibition of either
ALDH1A2 activity or RAR-dependent transcription.
Inhibition of ALDH1A2-RAR signaling in vitro revealed
a mesenchymal-like phenotype, which was characterized
by loss of cell-to-cell adhesion, accelerated migration and
induced expression of markers indicating induction and
maintenance of epithelial-to-mesenchymal transition, such
as vimentin, N-cadherin, fibronec tin and Twist [20, 21].
The inverse correlation between ALDH1A2 and vimentin
expression in tumor cells was further supported in a
mouse xenograft model in vivo and tumor sections from
OPSCC patients. Although, the underlying molecular
mechanism remains to be elucidated, several studies re-
ported that ATRA inhibits tumor cell invasion and meta-
static potential in diverse model systems by modulating
cell-to-cell adhesion and RAR-dependent regulation of
proteins implicated in epithelial-to-mesenchymal transi-
tion [22–25]. It is also worth noting that a continuous cul-
tivation of FaDu cells in the presence of WIN18.446 or
BMS493, respectively, results in formation of stable and
expandable tumorspheres, suggesting that tumor cells
lacking ALDH1A2-RAR signaling also gain the capacity to
avoid anoikis and acquire stem cell traits (unpublished
data). However, the reduced cell-matrix adhesion upon in-
hibition of ALDH1A2-RAR signaling could cause a certain
bias concerning the interpretation of accelerated migra-
tion in 2D as it is quite likely that a substantial amount of
inhibitor-treated cells were lost over time by cell detach-
ment. In line with this assumption, administration of
higher amounts of WIN18.446 (data not shown) or the
more potent inhibitor BMS493 did not improve cell motil-
ity, despite increased cell scattering and a more prominent
mesenchymal-like phenotype. This raises the attractive
question, whether HNSCC cells in the absence of
ALDH1A2-RAR signaling gain the capacity of single cell
and amoeboid-like migration, which should be addressed
in more sophisticated models of 3D migration in future
studies. Furthermore, it will be a major challenge to un-
ravel critical downstream targets as well as relevant inter-
actions between ALDH1A2-RAR signaling and other key
regulators of mesenchymal transition as well as stem cell
traits, especially those that have been shown to correlate
with tumor cell dissemination and treatment failure of
HNSCC patients [20, 21].
Conclusions
Based on these findings, we speculate that a subgroup of
HNSCC patients at high risk for treatment failure under
currently established therapeutic regimens might benefit
from an adjuvant treatment with retinoids to restore
ALDH1A2-RAR signaling in tumor cells. Administration
of retinoids as chemopreventive strategy for premalig-
nant lesions or as a therapeutic option for HNSCC was
tested in several clinical trials [26–30]. Despite initial en-
couraging results this class of compounds was not trans-
lated into clinical practice due to intrinsic resistance to
retinoids, the toxic profile and lack of reliable bio-
markers to predict treatment responders [31]. Mean-
while, new compounds with improved pharmacology
and reduced toxicity are available and the lack of
ALDH1A2 expression could serve as an attractive bio-
marker to stratify HNSCC patients, who might benefit
from an adjuvant treatment with these new synthetic
retinoids.
Methods
Patient samples and tissue microarray
Tumor specimens for this retrospective study were ob-
tained from oropharyngeal squamous cell carcinoma
(OPSCC) patients, who were treated at the University
Hospital Heidelberg between 1990 and 2008. Paraffin-
embedded tissue specimens were provided by the tissue
bank of the National Center for Tumor Disease (Insti-
tute of Pathology, University Hospital Heidelberg) after
approval by the local institutional review board (ethic
vote: 206/2005). The study was performed according to
the ethical standards of the Declaration of Helsinki. For
all tumor samples, clinical and follow-up data were avail-
able from the Department of Otolaryngology, Head and
Neck Surgery at the University Hospital Heidelberg and
are listed in Additional file 2: Table S3-4. HPV16 DNA
and viral transcript status for patients of the cohort was
determined previously [32], and generation of tissue mi-
croarrays has been described elsewhere [33].
Immunohistochemical staining and scoring system
Tissue microarrays and tumor sections were incubated
with antibodies that are listed in Additional file 2: Table
S1. Immunostaining was visualized with the TSA Ampli-
fication Kit (Perkin Elmer, Rodgau, Germany) and DAB
peroxidase substrate (Vector Laboratories, Burlingame,
USA) according to the manufacturers instructions.
Counterstaining was done by hematoxylin to visualize
tissue integrity. Specificity of antibodies used in this
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study to detect expression of ADL1A2 (HPA010022),
CRABP2 (HPA004135) and RARβ (HPA004174) was
confirmed by similar staining patterns comparing experi-
mental data on our TMAs and those provided by
www.proteinatlas.org. Staining specificity of antibodies
used to detect expression of FABP5 (ab84028), RARα
(WH0005914M1) and PPARβ/δ (ab137724) was con-
firmed by IHC staining on serial TMA sections using in-
dependent antibodies, respectively (data not shown).
Bright field pictures were taken with the Nikon Eclipse
Ti microscope using the Nikon Imaging Software NIS-
Elements 3.20.02. Stained tissue microarrays were scanned
using the Nanozoomer HT Scan System (Hamamatsu
Photonics, Japan). Protein expression was evaluation by
three independent observers using the NDP Viewer soft-
ware (version 1.1.27) and considering the relative amount
of positive tumor cells (score 1 = no positive cell,
score 2 ≤ 33 %, 33 % > score 3 ≤ 66 %, score 4 > 66 %) and
the staining intensity (score 1 = no staining, score 2 =
weak staining, score 3 = moderate staining, score 4 = high
staining) as described previously [8]. Both scores were
multiplied to calculate the final immunoreactivity score
(IRS, range 1–16) and the cut-off values for subgroups
with high versus low protein levels was IRS = 4 for
CRABP2, IRS = 6 for FABP5, IRS = 9 for RARα, RARβ,
and PPARβ/δ, respectively.
Statistical analysis
Statistical analysis was done using SPSS (version 19) and
SAS (version 9.2) statistics software. Differences between
the groups were assessed using Chi square test or Fisher’s
exact test. Overall survival was calculated as the time from
the date of first-line therapy to the date of tumor-related
death within the follow-up interval (events). Survival time
of patients who were alive or were dead due to causes
other than OPSCC were censored. Progression-free sur-
vival was calculated from the date of primary therapy to
the date of the first local recurrence, lymph node or dis-
tant metastasis, second primary carcinoma or date of
tumor-related death within the follow-up period (events),
or to the date of OPSCC-unrelated death or without pro-
gression (censored). The method of Kaplan–Meier was
used to estimate survival distributions and differences be-
tween groups were determined by log-rank tests. A multi-
variate Cox proportional hazard model was used to assess
the association between protein expression scores and
overall or progression-free survival of cancer patients, to-
gether with the covariates age, gender, clinical stage, alco-
hol or tobacco consumption, first-line therapy and HPV
status. The validity of the proportional hazards assump-
tion was tested with the Supreme Test for proportional
hazards assumption and was met for all covariates. In all
statistical tests, a p-value of 0.05 or below was considered
as statistically significant.
Cell culture experiments
Human cell lines SCC25, FaDu and Cal27 were purchased
from ATCC (http://www.lgcstandards-atcc.org/), Detroit
562 from CLS (Cell Lines Service GmbH, Eppelheim,
Germany) and UMSCC-17B were kindly provided by Dr. I.
Tinhofer (Charité Universitätsmedizin Berlin, Germany).
Lau2068, Lau2073, Lau2081, Lau2104 and Lau2105 were
established from tumors of HNSCC patients, who were
treated at the University Hospital Lausanne, Switzerland.
All tumor cell lines were maintained in Dulbecco’s Modi-
fied Eagle’s Medium (Sigma, Germany) supplemented with
10 % fetal bovine serum (Invitrogen, Germany), 2 mM
L-Glutamine (Invitrogen, Germany) and 50 μg/ml Penicillin-
Streptomycin (Invitrogen, Germany) in a humidified atmos-
phere of 6 % CO2 at 37 °C. Authentication of commercial
available cell lines was confirmed by the Multiplex Human
Cell Line Authentication Test (Multiplexion, Germany).
For colony formation assays 300–1,000 FaDu, Cal27,
Detroit562 or UMSCC-17B cells were seeded per 6-well
plate. Cells were treated with the indicated concentra-
tion of ATRA (Sigma Aldrich, Germany), Adapalene
(Santa Cruz Biotechnology, US) or Fenretinide (Tocris
bioscience, UK) every second day for two weeks. To de-
termine the impact of ATRA on radiosensitivity, FaDu,
Cal27, Detroit562 or UMSCC-17B cells were treated
with the indicated concentration of ATRA or DMSO as
control and irradiation was done once with a dose of 2
Gy (X-RAD 320, Precision X-Ray, North Branford, CT
USA). After two weeks colonies were PFA-fixed and the
number of colonies was determined after crystal violet
staining as described in [34]. The survival fraction was
computed according to [35].
Cell proliferation of control (DMSO) and ATRA
treated (3 and 30 μM) tumor cells was determined by a
BrdU incorporation assay as described previously [20].
FaDu, Detroit 562 and UMSCC-17B cells were cultured
in the presence of either WIN18.446 (Santa Cruz Biotech-
nology, US) or BMS493 (Sigma Aldrich, Germany) at the
indicated concentrations with medium exchange and inhibi-
tor administration every two to three days. DMSO-treated
cells served as control. Bright field and phase contrast
pictures were taken with the Nikon Eclipse Ti micro-
scope using the Nikon Imaging Software NIS-Elements
3.20.02. Fluorescence staining of the actin cytoskeleton
with Phalloidin-Alexa Fluor 488 (Invitrogen, Germany)
and nuclear staining with Hoechst 33342 (Calbiochem
Merck, Germany) was done as described elsewhere [36].
The scratch wounding assay with Detroit562 and FaDu
cells was done as described elsewhere [37].
Protein isolation and Western blot analysis
Whole cell protein lysate was extracted using RIPA
(Radioimmunoprecipitation assay) buffer [38] and prote-
ase and phosphatase inhibitor cocktails (Sigma-Aldrich).
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20 μg of denatured protein were separated by Sodium-
dodecylsulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to polyvynil difluoride (PVDF)
membranes (Millipore, Germany). After blocking with 5 %
milk (Roth, Germany), membranes were incubated with
primary and horseradish peroxidase coupled-secondary
antibodies, which are listed in Additional file 2: Table S2.
Membranes were incubated in enhanced chemiluminis-
cence solution (Thermo Scientific, Germany) and devel-
oped with a classic E.O.S. developer (Agfa, Germany).
Quantification of intracellular RA levels by HPLC
Intracellular RA levels were measured as previously de-
scribed [39, 40]. Briefly, 5×106 cells were re-suspended
in 500 μl of 200 mM acetic acid and distributed by pass-
ing 20 times through a needle of a syringe. To an aliquot
(150 μl) of this cell suspension, 200 pmol of the syn-
thetic retinoid Acitretin (25 μl; 20 μM in 100 % ethanol,
Sigma Aldrich) was added as an internal standard. Two
volumes (320 μl) ice-cold 100 % ethanol was added and
samples were vortexed briefly. Hexane (2.5 volume; 1200
μl) was added to each sample and carefully vortexed for
1 min followed by centrifugation (5000 rpm, 20 min;
4 °C). The upper, organic, phase was then transferred to
a clean glass tube and dried by centrifugal evaporation
(30 °C; 40 min). The resulting residue was dissolved in
methanol/acetonitrile (50:50) + 0.1 % acetic acid (30 μl),
then diluted to a final volume of 100 μl with 10 mM am-
monium acetate + 0.1 % acetic acid, and transferred to
an amber HPLC vial and analysed. The RA analytes were
separated by HPLC (Hitachi Chromaster HPLC, VWR
International GmbH, Germany) using Zorbax Eclipse
XDB C18 columns (Agilent Technologies, US). The col-
umn was eluted with 10 mM ammonium acetate + 0.1 %
acetic acid and acetonitrile + 0.1 % acetic acid (20:80 %)
with a linear gradient over 15 min to 100 % acetonitrile +
0.1 % acetic acid. The flow was 0.25 ml/min and column
temperature at 30 °C. The RA analytes were detected by
absorbance monitoring at 385 nm. The concentration on
RA analytes was determined from serial dilutions (10–
1000 pmol) of ATRA spiked into artificial plasma (150 μl),
which were then processed as described. Calibration
curves were constructed by plotting the peak area ratio of
the RA analytes and internal standard (Acitretin) against
the respective concentration. The results were normalized
by total protein concentration of cell lysates. Protein con-
centrations were measured with the BCA Protein Assay
Kit (Pierce Biotechnology, US).
RNA extraction, cDNA synthesis and RT-PCR analysis
Total RNA from tumor cell lines was isolated with the
RNeasy Mini Kit (Qiagen, Germany) following the manu-
facturer’s instruction. Genomic DNA digestion was per-
formed with RNase-free DNAse Set (Qiagen, Germany).
Quantity and quality of isolated RNA was determined
with the help of the Nanodrop Spectrophotometer ND-
1000 (peqlab, Germany). cDNA synthesis and quantitative
RT-PCR was performed as described previously [41]. An-
nealing temperatures and sequences of all primers are
listed in Additional file 2: Table S2. The cycle of threshold
(CT) of the gene of interest was standardized to the CT
value of the reference gene using the ΔΔCT method. For
each primer pair, primer efficiency was determined by a
dilution series from 0.01 to 100 ng of a cDNA mix of ref-
erence samples. A primer efficiency of 1.8 to 2.0 was ac-
cepted for further analysis.
Generation of stable FaDu clones
FaDu cells were transfected with either a control pRS vec-
tor encoding a non-effective Hush 29-mer scrambled
shRNA cassette (TR30012, OriGene Technologies, USA)
or a pRS-shALDH1A2 plasmid (TR306766C, OriGene
Technologies, USA) using FuGene HD Transfection
Reagent (Promega, Germany) according to the manufac-
turer’s instruction. Following selection with 1 μg/ml Puro-
mycin (Gibco life technologies, Germany) for one week,
stable clones were established and efficient silencing of
ALDH1A2 expression was confirmed on protein level.
Mouse xenograft model
Animal experiments were approved by the Vaud Cantonal
Veterinary Office and conducted in accordance with
guidelines of the Ethics Committee for Animal Experi-
mentation of the Swiss Academy of Medical Sciences.
Athymic female 8-week-old NMRI-nu mice were pur-
chased from JANVIER LABS (Le Genest-Saint-Isle,
France). Mice were housed in groups of 5 and had access
to water and food ad libitum at the University of
Lausanne (UNIL) animal facility. 8×105 cells in a 30 μl
HBSS cell suspension were injected with 20 μl Matrigel
(BD Biosciences) into the subcutaneous tissue of the an-
terior floor of mouth approximately 3 mm caudal to the
mandible under isoflurane anesthesia. Tumor size was
measured by a caliper and calculated as V = (L×W2)/2
twice a week. During the time period of tumor growth no
animal showed cachexia (weight loss > 15 %) or any signs
of behavioral disturbance. When the tumor volume
reached a maximum size of 250 mm3, mice were eutha-
nized by CO2 inhalation, and tumor samples were divided
into fragments which were snap-frozen in liquid nitrogen
for molecular analyses or fixed with 4 % paraformaldehyde
and embedded with paraffin for histological analyses.
Additional files
Additional file 1: Figure S1. Association between subgroups with high
or low protein expression of CRABP2 (A), FABP5 (B), RARα (C), RARβ (D)
or PPARα/δ (E) and overall survival of OPSCC patients was assessed by
Seidensaal et al. Molecular Cancer  (2015) 14:204 Page 11 of 13
univariate Kaplan-Meier analysis. (F) Kaplan-Meier analysis demonstrates
overall survival probability for subgroups with indicated staining patterns for
ALDH1A2, CRABP2 and FABP5. Number at risk indicates the total amount of
patients per subgroup, which were alive and not censored at the indicated
time points and were considered to calculate the overall survival probability.
P values were calculated by log-rank tests. (TIF 1257 kb)
Additional file 2: Table S1. List of primary and secondary antibodies.
Table S2. List of primer sequences for RT-PCR analysis. Table S3. Correlation
analysis for CRABP2 protein levels and clinical or pathological features of the
OPSCC cohort. Table S4. Correlation analysis for FABP5 protein levels and
clinical or pathological features of the OPSCC cohort. Table S5. Tumor
volume (in mm3) ± SD in mice (n = 4 per group) after injection with either
FaDu-mock or FaDu-shALDH1A2 clones. (DOCX 59 kb)
Additional file 3: Figure S2. ALDH1A2 expression in HNSCC cell lines and
morphological phenotype upon inhibition of ALDH1A2-RAR signaling.
Western blot analysis with whole cell lysate demonstrates protein expression
of ALDH1A2 and key regulators of RA signaling in UMSCC-17B, Detroit562,
FaDu, Cal27 and SCC25 cells (A), and ALDH1A2 protein levels in newly
established HNSCC cell lines from Lausanne (B). Detection of β-Actin served as
control for quantity and quality of protein lysates. Relative RA levels were
determined by HPLC analysis with whole cell lysate of untreated (C), and
DMSO-treated control or WIN18.446-treated Cal27 and FaDu cells (D). Bars
represent mean values ± SD of three independent replicates. Graphs indicate
relative survival fraction of Cal27 and FaDu cells, which were treated with the
indicated concentration of Adapalene (E) or Fenretinide (F). Data represent
mean values ± SD of three independent replicates. (TIF 301 kb)
Additional file 4: Figure S3. (A) Relative number of BrdU-positive FaDu,
Detroit562 and UMSCC-17B cells following treatment with indicated
concentrations of ATRA or DMSO as control. Bars represent mean values +
SD of three independent replicates. (B) Relative survival fraction of Cal27,
FaDu, Detroit562 and UMSCC-17B cells after single irradiation with (red line)
or without (blue line) a dose of 2 Gy in combination with ATRA treatment
(1–30 μM). (TIF 899 kb)
Additional file 5: Figure S4. (A) Representative phase contrast pictures
of FaDu, Detroit562 and UMSCC-17B cells, which were treated with
DMSO, 3 μM WIN18.446 or 3 μM BMS493 for four days. (B) Representative
fluorescent pictures of FaDu and Detroit562 cells, which were treated as
described in (A), and were stained with Phalloidin-Alexa488 (green
signal). Nuclear staining was done with H33342 (blue signal). Migration of
Detroit562 (C) and FaDu cells (D), which were treated with DMSO (white
bars), 3 μM WIN18.446 (grey bars) or 3 μM BMS493 (black bars), in a
scratch wounding assay was determined by the relative gap closure at
the indicated time points. * p value ≤ 0.05. (TIF 4129 kb)
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